RLAY

Relay Therapeutics, Inc. (RLAY) - 10-K Summary

Business Context and Reporting Period

Company: Relay Therapeutics, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: Relay is a clinical-stage precision medicine company utilizing its proprietary Dynamo® platform to discover small molecule therapies for cancer and genetic diseases. The company focuses on "Motion-Based Drug Design" to target proteins previously considered intractable. The lead product candidate is zovegalisib (RLY-2608), an allosteric, pan-mutant, isoform-selective PI3Kα inhibitor.

Key Financial Metrics (Year Ended Dec 31, 2025)

Note: The filing does not provide specific gross margin or operating margin percentages as the company has no product sales revenue and is pre-commercial.

Material Changes vs. Prior Period

• Revenue Increase: Revenue increased by $5.3 million (53%) to $15.4 million, driven by the recognition of $15.4 million from the Elevar Therapeutics licensing agreement (upfront, material transfer, and milestone payments). In 2024, revenue was primarily from a Genentech milestone.
• Expense Reduction: Total operating expenses decreased by $64.4 million (17%). R&D expenses dropped $57.7 million due to strategic streamlining of the research organization and reduced costs for the lirafugratinib program following the Elevar licensing deal. G&A expenses decreased $19.9 million, largely due to lower stock compensation.
• Net Loss Improvement: Net loss narrowed by $61.2 million to $276.5 million, reflecting the revenue increase and expense reductions.
• Collaboration Changes: The Genentech collaboration for migoprotafib was terminated without cause in January 2025. Conversely, the Elevar agreement for lirafugratinib was executed in December 2024, with revenue recognized in 2025.

Guidance, Outlook, and Management Commentary

• Clinical Progress:
  • Zovegalisib (Breast Cancer): Initiated the global Phase 3 ReDiscover-2 Trial in Q2 2025. In February 2026, the FDA granted Breakthrough Therapy designation for zovegalisib plus fulvestrant in PIK3CA mutant HR+/HER2- breast cancer. Interim data showed a median Progression-Free Survival (PFS) of 10.3 months and a Clinical Benefit Rate (CBR) of 67% in the ReDiscover Trial.
  • Zovegalisib (Vascular Anomalies): Initiated the Phase 1/2 ReInspire Trial in Q1 2025 for PIK3CA-related overgrowth spectrum (PROS).
• Liquidity Outlook: Management believes cash, cash equivalents, and investments of $554.5 million as of December 31, 2025, are sufficient to fund operations and capital expenditures into 2029.
• Strategic Focus: The company is prioritizing the PI3Kα franchise (zovegalisib) and has streamlined other programs to focus resources on high-value opportunities.
• Risks: Key risks include the uncertainty of clinical trial outcomes, the need for additional capital, reliance on third-party manufacturers, and potential regulatory delays. The company has never completed a large-scale pivotal trial.

Investor Verification Checklist

• Cash Runway: Verify the $554.5 million cash balance and the assumption that it funds operations through 2029, given the high burn rate (~$235 million operating cash outflow in 2025).
• Phase 3 Trial Enrollment: Monitor enrollment rates and data readouts for the ReDiscover-2 Phase 3 trial, which is critical for regulatory approval.
• Elevar Milestone Potential: Review the terms of the Elevar agreement regarding the potential $488 million in future regulatory and commercial milestones and tiered royalties.
• Genentech Termination Impact: Confirm that the termination of the Genentech agreement has no lingering financial or legal liabilities beyond the cessation of future milestone payments.
• Intellectual Property: Assess the status of patent applications for zovegalisib (expiring 2041/2042) and the co-ownership terms with D.E. Shaw Research.